<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Single-agent ramucirumab&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Single-agent ramucirumab<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for advanced esophagogastric adenocarcinoma: Single-agent ramucirumab<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 14 days.<br/> <strong>Duration of therapy:</strong> Treatment is continued until disease progression, unacceptable toxicity, or patient withdrawal. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr class="divider_bottom"> <td>Ramucirumab</td> <td>8 mg/kg IV</td> <td>Dilute with NS to a total volume of 250 mL.*<sup>¶</sup> The first dose should be administered over 60 minutes. If tolerated, subsequent infusions may be administered over 30 minutes.<sup>[2]</sup></td> <td>Day 1</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>MINIMAL (&lt;10%).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedicate with an IV H1 receptor antagonist prior to each infusion.<sup>[2]</sup></li> <li>For patients who have experienced a grade 1 or 2 infusion-related reaction, premedicate with an H1 receptor antagonist, dexamethasone (or equivalent), and acetaminophen prior to each subsequent infusion.<sup>[2]</sup></li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Baseline liver dysfunction</strong></td> <td colspan="3"> <ul> <li>Patients with pre-existing Child-Pugh B or C liver dysfunction may develop new-onset or worsening encephalopathy, ascites, or hepatorenal syndrome during treatment with ramucirumab. Use in patients with Child-Pugh B or C cirrhosis only if the potential benefits of treatment are judged to outweigh the risks.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Cardiovascular issues</strong></td> <td colspan="3"> <ul> <li>Control hypertension prior to initiating treatment.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, cardiovascular effects.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs/symptoms of infusion reaction.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential, serum electrolytes, and liver and renal function tests at baseline and prior to each treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Prior to each new cycle, assess changes in blood pressure, neurologic symptoms, signs of GI perforation, and risk for bleeding and/or blood clots prior to each treatment. Periodically assess urine protein concentration by dipstick and/or routine urinalysis.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor thyroid function periodically during treatment.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Infusion-related reaction</strong></td> <td colspan="3"> <ul> <li>Manage symptoms per institutional standards.</li> <li>Reduce the infusion rate by 50% for grade 1 to 2 reactions.<sup>[2]</sup></li> <li>Permanently discontinue for grade 3 to 4 reactions.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiovascular toxicity</strong></td> <td colspan="3"> <ul> <li>Withhold ramucirumab for severe hypertension until medically controlled.</li> <li>Dose adjustment may be needed for ≥grade 2 hypertension.<sup>[1]</sup></li> <li>Permanently discontinue for medically significant hypertension that cannot be controlled with antihypertensive therapy or hypertensive crisis or hypertensive encephalopathy.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, cardiovascular effects.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Wound healing</strong></td> <td colspan="3"> <ul> <li>Withhold ramucirumab for 28 days prior to elective surgery.</li> <li>Do not administer ramucirumab for at least 28 days following a major surgical procedure and until the wound is fully healed.</li> <li>Discontinue ramucirumab in patients who develop wound healing complications that require medical intervention.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Proteinuria</strong></td> <td colspan="3"> <ul> <li>For urine dipstick 2+ or greater, perform a 24-hour urine collection for protein measurement. Withhold ramucirumab for urine protein ≥2 g over 24 hours. Reinitiate therapy at reduced dose<sup>[2]</sup> once urine protein returns to &lt;1.5 to 2 g over 24 hours. Permanently discontinue in the setting of nephrotic syndrome.</li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>Discontinue ramucirumab for serious hemorrhage, arterial thromboembolism, gastrointestinal perforation, or RPLS.<sup>[2]</sup> Discontinue therapy for a grade 3 or 4 venous thromboembolic event that is considered to be life threatening or that cannot be adequately treated with low-molecular-weight hepatin-based therapy, or that developed during anticoagulant therapy.<sup>[1]</sup></li> <li>Refer to UpToDate topics on toxicity of molecularly targeted antiangiogenic agents, non-cardiovascular effects and toxicity of molecularly targeted antiangiogenic agents, cardiovascular effects.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; CBC: complete blood count; GI: gastrointestinal; RPLS: reversible posterior leukoencephalopathy syndrome; NS: normal saline.<br/>* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Ramucirumab is incompatible with dextrose-containing solutions.<sup>[2]</sup><br/>¶ Infuse through a separate infusion line using an infusion pump; the use of an 0.22-micron protein-sparing filter is recommended. Do not administer as an IV push or bolus. Flush the line with NS* after infusion is complete. Do not infuse in the same IV line with solutions other than NS*, or with electrolytes or other medications.</div><div class="graphic_reference">References: 

<ol>
<li>Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31.</li>
<li>Ramucirumab. United States Prescribing Information. US National Library of Medicine. Available at <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf</a> (Accessed on August 19, 2021).</li></ol></div><div id="graphicVersion">Graphic 132474 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
